Benzothiazole compounds and medical application

A technology of benzothiazole and compounds, applied in the field of medicinal chemistry, to achieve the effects of cheap raw materials, easy large-scale production, and easy availability of raw materials
CN111763201AInactive Publication Date: 2020-10-13CHINA PHARM UNIV
1 Cites 2 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
CHINA PHARM UNIV
Publication Date
2020-10-13
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses a benzothiazole compound and medical application thereof, particularly relates to a benzothiazole compound shown as a formula I and medical application thereof, and especiallyrelates to application of the benzothiazole compound serving as a USP7C-terminal structural domain regulating agent in medicines for preventing and treating myelodysplastic syndromes and malignant tumors. The benzothiazole compound shown in the formula I or the pharmaceutically acceptable salt or solvate of the benzothiazole compound has strong binding force with USP7C-terminal protein; and the protein level of DNMT1 in tumor cells can be reduced, so that the compound can be applied to the preparation of USP7 regulators, has a remarkable anti-tumor cell proliferation effect, and can be used for preparing medicines for preventing or treating myelodysplastic syndrome and malignant tumors.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The present invention relates to the field of medicinal chemistry, in particular to benzothiazole compounds and their use in pharmaceuticals, especially to benzothiazole compounds and their use as USP7 C-terminal domain regulators in the prevention and treatment of myelodysplastic syndromes and malignant tumors use in . Background technique

[0002] Myelodysplastic syndromes (myelodysplastic syndromes, MDS) are a group of heterogeneous myeloid clonal diseases originating from hematopoietic stem cells, characterized by abnormal differentiation and development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenias, high Risk of conversion to acute myeloid leukemia (AML). The main causes of death of the patients were the complications caused by the disease itself and the death caused by transformation to AML (Cancer 2010,16:2174-2179). According to statistics, in the United States, its prevalence rate is about 0.004-0.005%, and...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More